Skip to main content
. 2017 Nov 2;18(11):2305. doi: 10.3390/ijms18112305

Figure 6.

Figure 6

(A–D) Effects of dual therapy with IGF1R/IR and AR antagonists on TNBC proliferation. TNBC cells were grown in 96-well plates to 50–60% confluence in complete media. (A) Cells were maintained in phenol red-free RMPI 1640 media supplemented with 2% cFBS and either NVP-AEW541 (8 μM, IGF1R inhibitor; Selleckchem) or BMS-754807 (20 μM, IGF1R/InsR inhibitor; Selleckchem), alone or in combination; (B) Cells were exposed to media containing enzalutamide (20 μM, AR inhibitor; Selleckchem) and proliferation was assessed after 72 h; (C) Cells were cultured in media containing BMS-754807 and enzalutamide for 72 h or (D) in media containing NVP-AEW754 and enzalutamide for 72 h. Thereafter, cell proliferation was measured using the Celltiter 96® Aqueous Proliferation Assay (Promega, Madison, WI, USA). # p-value < 0.05, * p-value < 0.001. SD: standard deviation (n = 3).